PCSK9 and coronary artery disorder: Using the data from the STable Coronary Artery Diseases RegisTry (START) [17] and the EYESHOT (EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in iTaly) Post-MI [18], two Italian contemporary, nationwide registries on patients with stable coronary artery disease (CAD), we sought to describe the lipid lowering therapies prescribed in those with a prior MI and the resulting eligibility for PCSK9 inhibitors according to the criteria recommended by ESC/EAS and Italian regulatory agency.